XPH icon

SPDR S&P Pharmaceuticals ETF
XPH

Overview Fund Activity

65 hedge funds and large institutions have $110M invested in SPDR S&P Pharmaceuticals ETF in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 13 closing their positions.

Holders
65
Holders Change
-6
Holders Change %
-8.45%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
23
Reduced
19
Closed
13
Calls
$2K
Puts
$932K
Net Calls
-$930K
Net Calls Change
-$80K

Top Buyers

1
RJFSA
1
Raymond James Financial Services Advisors
Florida
$13.5M
2
Morgan Stanley
2
Morgan Stanley
New York
$31.3M
3
Goldman Sachs
3
Goldman Sachs
New York
$5.47M
4
CI
4
CX Institutional
Indiana
$3.17M
5
Bank of America
5
Bank of America
North Carolina
$11.2M

Top Sellers

1
CCMG
1
Clark Capital Management Group
Pennsylvania
$0
2
JPMorgan Chase & Co
2
JPMorgan Chase & Co
New York
$14K
3
Envestnet Asset Management
3
Envestnet Asset Management
Illinois
$1.19M
4
Ameriprise
4
Ameriprise
Minnesota
$2.34M
5
UBS Group
5
UBS Group
Switzerland
$16.2M
Name Market Value Shares Shares
Change 		Shares
Change %
AIC
76
Archer Investment Corporation
Indiana
– – -570 Closed
SWM
77
Spire Wealth Management
Virginia
– – -240 Closed
GWM
78
Geneos Wealth Management
Colorado
– – -106 Closed
HNB
79
Huntington National Bank
Ohio
– – – –
1 2 3
4